EptifibatidePlatelet glycoprotein IIb/IIIa inhibitor
Eptifibatide prevents platelets from binding together through a key surface receptor. It has been studied in acute coronary care, where reducing clot formation must be weighed against bleeding.
What is Eptifibatide?
Eptifibatide is a cyclic peptide antiplatelet medicine used in selected acute coronary and coronary-intervention settings. Its purpose is to reduce platelet-driven clot formation. 2 3
How it works
It blocks platelet glycoprotein IIb/IIIa receptors, preventing fibrinogen from linking platelets together. This acts on platelet aggregation rather than directly inhibiting thrombin. 1 3
Effects studied
Acute coronary events
PURSUIT studied clinical outcomes in acute coronary syndromes. Its results need to be interpreted alongside the treatment regimens and procedural practice of that period.
Evidence: Randomised acute coronary syndrome trial. 2
What does the evidence show?
Acute-coronary-syndrome trial and prescribing-information lead
How it prevents platelets from joining
Eptifibatide is a cyclic peptide that inhibits the platelet glycoprotein IIb/IIIa receptor. This receptor helps platelets link through proteins such as fibrinogen. Blocking it interrupts aggregation, a different step from directly inhibiting thrombin in the coagulation cascade.
Why timing matters in coronary care
A developing coronary clot or a coronary intervention can create a need for rapid antiplatelet activity. Eptifibatide is assessed within a package of treatment that may include other antiplatelets, anticoagulants and a procedure. That context determines both the expected benefit and the total bleeding risk.
What an older trial can establish
The retained PURSUIT study examined acute coronary syndrome using the treatment patterns of its time. It contributes important evidence, but a result against that comparator is not automatically the answer for every modern catheter-based strategy. Absolute risks and the use of other medicines can change the balance. 2
Bleeding and platelet counts are central
Serious bleeding and thrombocytopenia, a fall in platelet count, are key concerns. Kidney function affects the clinical assessment, and combinations with other clot-preventing medicines need close management. This hospital antiplatelet medicine is used in selected clinical situations where the expected benefit justifies the bleeding risk. 3
Safety & status
Bleeding and low platelet counts are important risks. Kidney function affects product use, and concurrent antithrombotic medicines influence the overall bleeding risk. 3
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Does it dissolve an existing clot?
Its primary action is preventing platelet aggregation, not directly dissolving clot material. 3
Is it equivalent to a direct thrombin inhibitor?
No. Both can reduce clotting but act on different parts of the process and have different clinical roles. 3
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.